Business Description
GT Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US6918295014
Compare
Compare
Traded in other countries / regions
GTBP.USAOXIA.GermanyGTBP.France0RU9.UK IPO Date
2005-08-31Description
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 240.9 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 68.3 | |||||
| 3-Year EPS without NRI Growth Rate | 60.5 | |||||
| 3-Year FCF Growth Rate | 49.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.43 | |||||
| 9-Day RSI | 26.37 | |||||
| 14-Day RSI | 31.27 | |||||
| 6-1 Month Momentum % | -28.38 | |||||
| 12-1 Month Momentum % | -55.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.12 | |||||
| Quick Ratio | 2.12 | |||||
| Cash Ratio | 2.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -99.5 | |||||
| Shareholder Yield % | -118.95 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -70.3 | |||||
| ROA % | -44.57 | |||||
| ROIC % | -3139.69 | |||||
| ROC (Joel Greenblatt) % | -6604.65 | |||||
| ROCE % | -61.9 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.69 | |||||
| Price-to-Tangible-Book | 0.69 | |||||
| EV-to-EBIT | 1.18 | |||||
| EV-to-EBITDA | 1.18 | |||||
| EV-to-FCF | 0.99 | |||||
| Price-to-Net-Current-Asset-Value | 0.7 | |||||
| Price-to-Net-Cash | 0.71 | |||||
| Earnings Yield (Greenblatt) % | 84.75 | |||||
| FCF Yield % | -170.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GT Biopharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -5.171 | ||
| Beta | 0.7 | ||
| Volatility % | 49.76 | ||
| 14-Day RSI | 31.27 | ||
| 14-Day ATR (€) | 0.003059 | ||
| 20-Day SMA (€) | 4.77 | ||
| 12-1 Month Momentum % | -55.34 | ||
| 52-Week Range (€) | 4.77 - 10.74 | ||
| Shares Outstanding (Mil) | 1.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GT Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GT Biopharma Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
GT Biopharma Inc Frequently Asked Questions
What is GT Biopharma Inc(FRA:OXIA)'s stock price today?
The current price of FRA:OXIA is €4.77. The 52 week high of FRA:OXIA is €10.74 and 52 week low is €4.77.
When is next earnings date of GT Biopharma Inc(FRA:OXIA)?
The next earnings date of GT Biopharma Inc(FRA:OXIA) is 2024-05-15 Est..
Does GT Biopharma Inc(FRA:OXIA) pay dividends? If so, how much?
GT Biopharma Inc(FRA:OXIA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers